Skip to main content
Premium Trial:

Request an Annual Quote

China Approves Sinopharm Vaccine

China has approved a SARS-CoV-2 vaccine developed by the state-owned company Sinopharm, NPR reports.

It adds that the vaccine from Sinopharm subsidiary China National Biotec Group, or CNBG, relies on an inactivated coronavirus to spur the production of antibodies and, according to the company, has a 79 percent efficacy rate. A trial conducted in the United Arab Emirates previously suggested the Sinopharm vaccine had an 86 percent efficacy rate, a finding that led the UAE to officially register the vaccine.

NPR reports that the approval is conditional and requires Sinopharm to continue to collect data on the vaccine, which is given in a two-dose regimen. The Guardian adds that China hopes to reach between 60 percent and 70 percent immunization coverage, noting that about a million people have already received the Sinopharm vaccine under emergency approvals. "As the Chinese vaccine is proved to be safe and effective, we would like to encourage our people to participate on a voluntary and informed basis, and with consent," said Zeng Yixin, deputy head of the national health commission, according to the Guardian.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.